Pharvaris (PHVS) Interest Expenses (2021 - 2026)
Pharvaris' (PHVS) quarterly Interest Expenses came in at -$128.4 billion in Q3 2024, up 50.04% on a QoQ basis from -$257.0 billion in Q4 2023.
Analysis
Pharvaris (PHVS) Interest Expenses (2021 - 2026) Analysis & Trends
Pharvaris (PHVS) has 5 years of Interest Expenses data on file, last reported at -$128.4 billion in Q3 2024.
- Quarterly Interest Expenses changed N/A year-over-year to -$128.4 billion in Q3 2024, while the trailing twelve-month figure through Sep 2024 was -$128.4 billion (down 191289232.56% YoY) and the FY2023 annual result came in at -$258.4 billion, down 624644381.68% from the prior year.
- Interest Expenses grew to -$128.4 billion in Q3 2024, from -$257.0 billion in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $297037.2 in Q2 2021 to a low of -$257.0 billion in Q4 2023.
- A 5-year average of -$32.1 billion and a median of $6801.0 in 2022 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2021 — Interest Expenses soared 535.92% — and 2023, when it plunged 382873551.54%.
- Tracing PHVS's Interest Expenses over 5 years: stood at $46709.6 in 2020, then slipped by 28.12% to $33574.4 in 2021, then slumped by 299.96% to -$67136.4 in 2022, then sank by 382873551.54% to -$257.0 billion in 2023, then soared by 50.04% to -$128.4 billion in 2024.
- The last three Interest Expenses figures came in at -$128.4 billion (Q3 2024), -$257.0 billion (Q4 2023), and -$67136.4 (Q4 2022), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Pharvaris | 2.13 Bn | 1.76 Bn | 85,072.10 | 4.12 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.12 Mn |
| Mar 31, 2026 | 6.26 Mn |
| Dec 31, 2025 | -1.23 Mn |
| Sep 30, 2025 | 6.93 Mn |
| Jun 30, 2025 | -5.55 Mn |
| Mar 31, 2025 | -4.05 Mn |
| Dec 31, 2024 | 12.36 Mn |
| Sep 30, 2024 | -3.93 Mn |
| Jun 30, 2024 | 5,084.58 Bn |
| Mar 31, 2024 | 2.25 Mn |
| Dec 31, 2023 | -3,133.83 Bn |
| Sep 30, 2023 | 2.99 Mn |
| Jun 30, 2023 | 709.62 Bn |
| Mar 31, 2023 | -1.60 Mn |
| Dec 31, 2022 | -90,754.06 |
| Sep 30, 2022 | 11.59 Mn |
| Jun 30, 2022 | 12,273.08 Bn |
| Mar 31, 2022 | 3.81 Mn |
| Jun 30, 2021 | -2.98 Mn |
| Mar 31, 2021 | 7.02 Mn |